Best Hospitals for Crohn's Disease Treatment in Hyderabad, India

Crohn's disease is a transmural, granulomatous inflammatory bowel disease that can affect any segment of the gastrointestinal tract from the mouth to the perianal region, most commonly involving the terminal ileum and proximal colon. Unlike ulcerative colitis, which is confined to the colonic mucosa, Crohn's inflammation penetrates all layers of the bowel wall, predisposing patients to fibrotic strictures, internal fistulae, intra-abdominal abscesses, and perianal septic complications. Disease behavior is classified using the Montreal Classification into inflammatory (B1), stricturing (B2), and penetrating (B3) phenotypes, with perianal disease designated separately (p). The heterogeneous nature of the disease demands individualized phenotype-driven treatment strategies.

• ELIGIBLE PATIENTS:
• Adults and adolescents (age ≥ 6 years under pediatric protocols) with confirmed Crohn's disease diagnosis based on endoscopic, histopathological, and cross-sectional imaging criteria
• Patients with moderate-to-severe active disease defined by CDAI ≥ 220, HBI ≥ 8, or elevated fecal calprotectin (> 250 µg/g) with concurrent mucosal inflammation on endoscopy
• Patients failing or intolerant to conventional therapy (corticosteroids, azathioprine, 6-MP, methotrexate) who are candidates for biologic or small-molecule (JAK inhibitor: upadacitinib) induction
• Patients with steroid-dependent or steroid-refractory disease requiring biologic optimization or combination immunosuppression
• +25 more

Medical (non-surgical) THERAPIES:

1. Induction and Maintenance with Biologic Agents:

• Anti-TNF Monoclonal Antibodies: Infliximab (IV infusion: 5 mg/kg at weeks 0, 2, 6, then every 8 weeks) and Adalimumab (SC injection: 160/80/40 mg induction, then 40 mg every 2 weeks) are first-line biologics for moderate-to-severe Crohn's. Combination with azathioprine (2.0–2.5 mg/kg/day) reduces immunogenicity and improves sustained remission rates (SONIC trial data: 56.8% corticosteroid-free remission with combination vs. 44.4% infliximab monotherapy at week 26). Therapeutic drug monitoring (TDM) of trough levels (infliximab target: > 3–7 µg/mL in maintenance) is now standard practice at high-quality IBD centers.
• Anti-Integrin Therapy (Vedolizumab): A gut-selective α4β7 integrin antagonist (IV: 300 mg at weeks 0, 2, 6, then every 8 weeks) with a superior safety profile. Preferred for patients with prior malignancy, demyelinating disease, or recurrent infections. Onset is slower (peak response at 14 weeks); optimal for maintenance in biologic-naive moderate disease.
• Anti-IL-12/23 (Ustekinumab): IV weight-based induction dose (~6 mg/kg), followed by SC 90 mg every 8–12 weeks. Highly effective in anti-TNF–experienced patients (UNIFI/IM-UNIFI data). Excellent safety profile; preferred in older patients or those with recurrent infections.
• JAK Inhibitors (Small Molecules): Upadacitinib (Rinvoq, 45 mg once daily induction for 12 weeks, then 30 mg or 15 mg maintenance) received FDA approval for moderate-to-severe Crohn's disease in 2023. Oral administration offers convenience. Monitoring required for lipid profile, CBC, and cardiovascular risk factors. Not recommended in patients > 65 years or with high cardiovascular risk.

2. Immunomodulators:

PHASE 1 — PRE-ARRIVAL PREPARATION (4–6 weeks before travel):

• Step 1: Submit medical records to GAF Healthcare (previous endoscopy reports, biopsy histopathology, MR enterography/CT enterography, operative notes if prior surgery, current medication list including biologic therapy details and TDM levels).
• Step 2: GAF Healthcare medical team conducts virtual tele-consultation with the treating gastroenterologist or colorectal surgeon in India or UAE. A personalized treatment plan is formulated (biologic optimization vs. surgical intervention).
• Step 3: Nutritional optimization initiated if pre-operative malnutrition is identified (serum albumin < 30 g/L): enteral nutrition support prescribed for 4–6 weeks; parenteral nutrition reserved for those with obstructing strictures.
• Step 4: Latent TB treatment initiated if QuantiFERON Gold positive (minimum 4 weeks of isoniazid before starting anti-TNF therapy).
• Step 5: Visa arrangement — Indian e-Medical Visa application submitted by GAF Healthcare with hospital invitation letter; UAE patients receive visa-on-arrival or e-Visa arranged by GAF team.
• Step 6: Biologic therapy bridging — for patients mid-course, scheduling of infusion (infliximab) or injection (adalimumab/ustekinumab) timed to coincide with hospital arrival.

PHASE 2 — ARRIVAL AND ADMISSION (Day 0–2):